It is unsurprising, therefore, that TP53 and ATM alterations are enriched in clinically advanced and treatment refractory CLL consequent upon natural selection of the ‘fittest’ CLL subclones harboring such defects (Table 1) [15,19,24]. The gene discussed is ATM; the disease is B-cell chronic lymphocytic leukemia.